Lexicon Pharmaceuticals | LXRX - Trade Debtors


Lexicon Pharmaceuticals reported $2.38M in Trade Debtors for its fiscal quarter ending in December of 2025.





Trade Debtors Change Date
Abbott USD 10.57B 171M Dec/2025
Acadia Pharmaceuticals USD 148.38M 153K Mar/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Akebia Therapeutics USD 47.03M 19.19M Dec/2025
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
AstraZeneca USD 17.88B 1.17B Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Eli Lilly USD 21.18B 1.02B Mar/2026
Esperion Therapeutics USD 140.19M 21.21M Dec/2025
Halozyme Therapeutics USD 457.99M 16.72M Mar/2026
Illumina USD 738M 116M Mar/2026
Insmed USD 178.55M 37.7M Mar/2026
Ironwood Pharmaceuticals USD 81.89M 5.68M Dec/2024
J&J USD 21.33B 3.72B Dec/2025
Lexicon Pharmaceuticals USD 2.38M 50K Dec/2025
MacroGenics USD 13.37M 55.86M Dec/2025
MannKind USD 28.14M 10.23M Mar/2026
Merck USD 11.78B 345M Dec/2025
Moderna USD 71M 113M Mar/2026
Novartis USD 9.6B 2.69B Mar/2026
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
Thermo Fisher Scientific USD 9.2B 304M Mar/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
United Therapeutics USD 312M 38.2M Mar/2026
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024